Alpha interferon (IFN-a) and nucleoside analogs have been shown to have synergistic antiherpesvirus activity in cultured cells. The mechanisms responsible for this synergistic activity are not known, but we hypothesize that IFN-a-induced alterations of nucleoside metabolism in virus-infected cells may play an important role. Infection of cells with herpes simplex virus type 1 (HSV-1) led to an increase in uptake of thymidine into cells. Treatment of infected cells with recombinant IFN-a for 24 h prior to infection resulted in a significant reduction in the uptake of exogenous thymidine but did not reduce the apparent incorporation of exogenous thymidine into DNA. The amount of exogenous thymidine phosphorylated relative to the amount taken up was the same in IFN-a-treated and control cultures. IFN-a treatment of HSV-1-infected cells also resulted in a reduction in the pool sizes of endogenous deoxyribonucleoside-5'-triphosphates relative to those of untreated HSV-1-infected cultures. Although IFN-a affected the metabolism of natural nucleosides in HSV-1-infected cells, it did not significantly reduce the uptake of the antiviral guanosine analog acyclovir into HSV-1-infected cells or the amount of acydovir-5'-triphosphate accumulated. Therefore, in IFN-a-treated cells the concentration of a natural nucleoside, thymidine, was reduced, as were the pools of all deoxyribonucleoside-5'-triphosphates. No decrease in acyclovir or acyclovir-5'-triphosphate concentration was observed, however, when acyclovir-treated cells were exposed to IFN-a. These data suggest that IFN-a-induced alterations in nucleoside metabolism may be one mechanism whereby IFN-a and acyclovir express synergistic antiherpesvirus activity.
Treatment of herpetic keratitis in humans with topical alpha interferon (IFN-a) combined with topical nucleoside analogs such as acyclovir (ACV) has been reported to reduce shedding of herpes simplex virus type 1 (HSV-1) and to require less time to healing than when IFN or a nucleoside analog is used alone (7-9, 11, 24, 25, 32-34) . Using cell cultures of human corneal stromal cells, we have shown that treatment with ACV and human recombinant IFN-a2 produces synergistic anti-HSV-1 activity (35) . Others have found similar synergistic antiherpes activities between other nucleoside analogs and IFN-a in a variety of cell types in culture (4, 10, 17) . Synergistic antiviral activity between nucleosides and IFNs has also been observed in cell cultures with other human herpesviruses, including varicella-zoster virus (2, 21) and cytomegalovirus (31) , and with human immunodeficiency virus (18) .
In order to rationally approach the use of combination treatment (with IFN and nucleoside analogs) against human herpesvirus-induced disease and to achieve maximum therapeutic efficacy with such treatment, it is essential to understand the mechanism by which the synergistic antiviral effects are achieved. One possible mechanism is that IFN directs a modification of nucleoside metabolism such that the analog is a more effective antiviral agent. In this study, we tested the effects of the combination of IFN and ACV on nucleoside metabolism. In this system, IFN alone has little detectable anti-HSV activity, while ACV alone functions as a selective anti-HSV nucleoside analog (12) . The combination of 100 IU of IFN-a per ml and 5 ,uM ACV used in this * Corresponding author. study was found to produce maximum measurable antiviral synergy (35) and complete protection of cells from HSV-1-induced cytopathic effect. IFN-a alone at this concentration had no detectable effect on viral cytopathic effect, while 5 ,uM ACV alone reduced viral cytopathic effect by approximately 50%. We have found that treatment of HSV-1-infected cells with human IFN-a results in a reduction in the intracellular pools of nucleosides and nucleotides with which ACV competes, while the amount of ACV taken into IFNa-treated, HSV-1-infected cells remains unaffected. These changes in nucleoside metabolism resulted in a decrease in the concentration of the natural nucleosides and nucleotides relative to the concentration of ACV and its phosphorylated forms, with which the natural nucleosides and nucleotides compete for HSV-1-specific enzymes. This alteration of nucleoside metabolism was detected only in HSV- To determine nucleoside uptake, the medium was removed and the cell layer was rinsed once with Hanks balanced salt solution. To harvest nucleosides, 3 ml of ice-cold 0.4 M perchloric acid (HCl04) was added and the cultures were held at 4°C for 30 min. The HC104 was removed and saved, the wells were rinsed once with 1 ml of ice-cold 0.4 M HC104, and the rinses were combined. Samples of the ice-cold HC104 were taken for liquid scintillation counting in order to quantitate the amount of nucleoside in the acid-soluble fraction.
The acid-insoluble fraction was harvested by flooding the wells with 1 ml of 0.3 M NaOH and then incubating them at 37°C for 18 h to hydrolyze the RNA and solubilize the acid-insoluble DNA. Samples of the NaOH-solubilized material were assayed for the amount of isotope present by liquid scintillation counting. Total uptake represented the sum of isotope in the acid-soluble and acid-insoluble samples.
Nucleotide pools were prepared and analyzed basically as we have previously described (6) . Cell cultures containing about 108 cells were infected and treated with IFN-a or ACV or both, as described above. The cells were harvested by trypsin treatment and washed in phosphate-buffered saline, and the nucleotides were extracted for 30 min in 1.5 ml of ice-cold 0.4 M HCl04 containing [14C]thymidine as an internal standard. The HC104 was neutralized by the addition of 0.33 g of alamine in 1.5 ml of trichlorotrifluoroethane. The mixture was vortexed and the aqueous phase was removed, filtered, and stored at -80°C. Deoxyribonucleotide content was determined by high-performance liquid chromatography following periodate treatment (6) . The acid-insoluble fraction was saved and assayed for DNA content (37) . The nucleotide pools were analyzed on a Partisil 10 SAX column (Whatman, Inc., Clifton, N.J.) eluted isocratically with 7 mM NaH2PO4 (pH 4.0) for 5 min, run on a linear gradient to 70% 1 M NaH2PO4 (pH 4.5) over 30 min, and held at 70% 1 M NaH2PO4 for 10 min. The flow rate was 1.5 ml/min. Nucleotides were detected by simultaneously measuring A260 and A280. Peaks were identified and quantitated by comparison of retention times, peak ratios, and peak areas with authentic standards.
Statistics. Comparisons of nucleoside uptake and incorporation between control and experimental cultures were made by using Student's t test.
Cell cycle analysis. Cells, treated with 100 IU of IFN-a per ml for 24 h or not treated, were stained with propidium iodine (20) for analysis of the number of cells in the population in each phase of the growth cycle. Analysis was performed on an EPICS V flow cytometer (Coulter Electronics, Inc., Hialeah, Fla.). 34, 1990 DISCUSSION IFN-a pretreatment of HSV-1-infected cells resulted in (i) inhibition of thymidine uptake; (ii) a corresponding decrease in the amount of thymidine detectable as mono-, di-, and triphosphates; (iii) little decrease in the incorporation of exogenous thymidine into DNA; (iv) no decrease in the uptake of ACV; and (v) a decrease in all native dNTP pools, especially dGTP. The decrease in dNTP pools in IFNa-treated cells was observed even when cells were treated with ACV. This observation is especially significant since we and others (30) have shown that ACV treatment alone leads to increased dNTP pools in HSV-1-infected cells. The decrease in dGTP pools while ACV triphosphate (ACVTP) pools remained unchanged resulted in a two-to threefold increase in the ratio of ACVTP to dGTP. Such an alteration (14) , changes in de novo and salvage pathways of thymidine synthesis (13) , and reduction in uptake of thymidine (19 
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